Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET

Company Participants

Ran Meir - SVP, Investor Relations

Richard Francis - President & CEO

Eli Kalif - CFO

Eric Hughes - Chief Medical Officer, Head of Research and Development

Sven Dethlefs - Head, North America Commercial

Conference Call Participants

Hassan Aftab - Bank of America Merrill Lynch

Umer Raffat - Evercore ISI

Balaji Prasad - Barclays

Ash Verma - UBS

Nathan Rich - Goldman Sachs

Chris Schott - JPMorgan

David Amsellem - Piper Sandler

Operator

Hello, and welcome to the Q1 2023 Teva Pharmaceutical Industries Limited earnings conference call. My name is Alex. I'll be coordinating the call today. [Operator instructions].

I'll now hand over to your host, Ran Meir, SVP of Investor Relations. Please go ahead.

Ran Meir

Thank you, Alex. Thank you, everyone, for joining us today. We hope you have had an opportunity to review our press release, which was issued earlier this morning. A copy of this press release, as well as a copy of the slides being presented on this call, can be found on our website at tevapharm.com.

Please review our forward-looking statement on Slide No. 2. Additional information regarding these statements and our non-GAAP financial measures is available on our earning release and in our SEC Forms 10-K and 10-Q. To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's Q1 2023 results and business performance, recent events, and priorities going forward.

Our CFO, Eli Kalif, will follow up by reviewing the financial results in more detail, including our 2023 financial outlook. Joining Richard and Eli on the call today are Sven Dethlefs, Teva's head of North America business; and Dr. Eric Hughes, our head of R&D and chief medical officer. They will be available during the question-and-answer session that will follow the presentation.

Please note that today's call will run approximately one hour. And with that, I will now turn the call over to Richard. Richard, if you would, please?

Richard Francis

Thank you, Ran. And good morning and good afternoon, everyone. Thank you also for joining us today. Now before I start getting to the Q1 results, I thought I'd just take a bit of time to give you my thoughts and impressions of the last few months I've had at Teva.

Now in short, impressed by many of the things I've seen and discovered while being around the world talking to many of our people, and it's because of this that I think we have real opportunity for the company, and maybe the company is underappreciated currently. Now let me go into sort of four areas I'd like to focus on here. Now I know most of you think of us as a generics company. And in truth, we are more than that.